Economic assessment in the management of non-Hodgkin’s lymphoma

Abstract

An increasing need for economic evaluations of non-Hodgkin’s lymphoma (NHL) treatments exists. We performed a literature review on the currently available NHL economic evaluations, using PubMed and the Cochrane database. English and Dutch language papers on treatment in adults were selected. A total of 88 publications were found, 44 of which were included. Of these, 6 economic evaluation-specific methodological items are evaluated (study perspective, overhead costs, data sources, charges or prices, sensitivity analysis, presentations of resource use and unit costs), enabling readers to judge the value of these studies. The 11 subjects covered by the economic evaluations are discussed. Many NHL treatments remain to be studied in economic evaluations. Future publications should report on the six methodological items in more detail, and preferably tackle them in the recommended way.

• antineoplastic combined chemotherapy protocols
• cost of illness
• costs and cost analysis
• drug therapy
• economics
• healthcare costs
• haematological neoplasms
• haematopoietic cell growth factors
• haematopoietic stem cell transplantation
• malignant lymphoma
• monoclonal antibodies
• Non-Hodgkins lymphoma
• stem cell transplantation